相关实验视频
Updated: Sep 18, 2025

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
9.7K
结直肠癌中的p53:从一个主角到一个特权的治疗目标
Sicheng Yan1, Fuyuan Zhan1,2, Yuxuan He1
1Huzhou Key Laboratory of Molecular Medicine, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang, Chinese Medical University, Huzhou, 313000, China.
Journal of translational medicine
|June 19, 2025
概括
大肠直肠癌 (CRC) 涉及TP53基因突变,使瘤抑制失效. 新的疗法旨在恢复p53功能或准其突变,以有效治疗CRC.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 结肠直肠癌 (CRC) 是全球主要的健康问题,在患病率上排名第三,死亡率排名第二.
- CRC的发病包括累积遗传突变,激活像KRAS这样的瘤基因,以及禁用像TP53.3这样的瘤抑制剂.
- 在CRC中,TP53瘤抑制基因经常发生突变 (约. 74%),破坏了其保护性细胞功能.
研究的目的:
- 审查p53在结直肠癌发病过程中的作用.
- 描述CRC中的TP53突变及其对疾病进展的影响.
- 总结针对CRC中的p53的当前和新兴治疗策略.
主要方法:
- 实验室和临床试验数据的文献综述.
- 对CRC中的p53功能和突变机制的分析.
- 综合关于治疗方法的信息,以p53.3为目标.
主要成果:
- 在CRC中TP53突变通过对野生类型p53的主导负抑制和功能获取活动而发生.
- 突变的p53颠覆细胞循环停止,细胞亡和DNA修复,促进瘤生长.
- 新兴疗法在重新激活p53,消耗突变物或使用免疫疗法方面表现有前途.
结论:
- p53在CRC中起着至关重要的作用,频繁的突变驱动瘤发生.
- 向p53突变体代表着对结直肠癌的有希望的治疗途径.
- 对p53向疗法的进一步研究可以显著改善CRC结果.
更多相关视频
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
DNA Damage can Stall the Cell Cycle
9.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
Negative Regulator Molecules
36.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.2K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K

